The Role of Macrophages in Cancer Development and Therapy

被引:210
作者
Cendrowicz, Ewa [1 ]
Sas, Zuzanna [2 ]
Bremer, Edwin [1 ]
Rygiel, Tomasz P. [2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, NL-9713 GZ Groningen, Netherlands
[2] Med Univ Warsaw, Dept Immunol, Nielubowicza 5 St,Bldg F, PL-02097 Warsaw, Poland
关键词
tumor-associated macrophages; immunotherapy; tumor microenvironment; tumor; immune suppression; macrophage; TUMOR-ASSOCIATED MACROPHAGES; PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER; DOWN-REGULATION; CELL-MIGRATION; PHASE-I; INFLAMMATION; ANGIOGENESIS; ANTIBODY; CD47;
D O I
10.3390/cancers13081946
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary: Tumor-Associated Macrophages (TAMs) play an important role in the development of tumors, modulation of neoangiogenesis, immune suppression, and metastasis. High infiltration of macrophages in the tumor is also correlated with poor prognosis in several cancer types. Therefore, they became an attractive target for cancer immunotherapies. In this review, we describe the role of macrophages in tumorigenesis and summarize the most recent advances in the therapies targeting TAMs. Macrophages are critical mediators of tissue homeostasis and influence various aspects of immunity. Tumor-associated macrophages are one of the main cellular components of the tumor microenvironment. Depending on their activation status, macrophages can exert a dual influence on tumorigenesis by either antagonizing the cytotoxic activity of immune cells or, less frequently, by enhancing antitumor responses. In most situations, TAMs suppress T cell recruitment and function or regulate other aspects of tumor immunity. The importance of TAMs targeting in cancer therapy is derived from the strong association between the high infiltration of TAMs in the tumor tissue with poor patient prognosis. Several macrophage-targeting approaches in anticancer therapy are developed, including TAM depletion, inhibition of new TAM differentiation, or re-education of TAM activation for cancer cell phagocytosis. In this review, we will describe the role of TAMs in tumor development, including such aspects as protumorigenic inflammation, immune suppression, neoangiogenesis, and enhancement of tissue invasion and distant metastasis. Furthermore, we will discuss therapeutic approaches that aim to deplete TAMs or, on the contrary, re-educate TAMs for cancer cell phagocytosis and antitumor immunity.
引用
收藏
页数:22
相关论文
共 186 条
  • [1] Toll-like receptors: critical proteins linking innate and acquired immunity
    Akira, S
    Takeda, K
    Kaisho, T
    [J]. NATURE IMMUNOLOGY, 2001, 2 (08) : 675 - 680
  • [2] The CCL5/CCR5 Axis in Cancer Progression
    Aldinucci, Donatella
    Borghese, Cinzia
    Casagrande, Naike
    [J]. CANCERS, 2020, 12 (07) : 1 - 30
  • [3] Trabectedin A drug from the sea that strikes tumor-associated macrophages
    Allavena, Paola
    Germano, Giovanni
    Belgiovine, Cristina
    D'Incalci, Maurizio
    Mantovani, Alberto
    [J]. ONCOIMMUNOLOGY, 2013, 2 (06)
  • [4] Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
    Anfray, Clement
    Ummarino, Aldo
    Torres Andon, Fernando
    Allavena, Paola
    [J]. CELLS, 2020, 9 (01)
  • [5] Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
    Ansell, Stephen M.
    Maris, Michael B.
    Lesokhin, Alexander M.
    Chen, Robert W.
    Flinn, Ian W.
    Sawas, Ahmed
    Minden, Mark D.
    Villa, Diego
    Percival, Mary-Elizabeth M.
    Advani, Anjali S.
    Foran, James M.
    Horwitz, Steven M.
    Mei, Matthew G.
    Zain, Jasmine
    Savage, Kerry J.
    Querfeld, Christiane
    Akilov, Oleg E.
    Johnson, Lisa D. S.
    Catalano, Tina
    Petrova, Penka S.
    Uger, Robert A.
    Sievers, Eric L.
    Milea, Anca
    Roberge, Kathleen
    Shou, Yaping
    O'Connor, Owen A.
    [J]. CLINICAL CANCER RESEARCH, 2021, 27 (08) : 2190 - 2199
  • [6] CCL2 as a potential therapeutic target for clear cell renal cell carcinoma
    Arakaki, Ryuichiro
    Yamasaki, Toshinari
    Kanno, Toru
    Shibasaki, Noboru
    Sakamoto, Hiromasa
    Utsunomiya, Noriaki
    Sumiyoshi, Takayuki
    Shibuya, Shinsuke
    Tsuruyama, Tatsuaki
    Nakamura, Eijiro
    Ogawa, Osamu
    Kamba, Tomomi
    [J]. CANCER MEDICINE, 2016, 5 (10): : 2920 - 2933
  • [7] Targeting Macrophage-Recruiting Chemokines as a Novel Therapeutic Strategy to Prevent the Progression of Solid Tumors
    Argyle, David
    Kitamura, Takanori
    [J]. FRONTIERS IN IMMUNOLOGY, 2018, 9
  • [8] The activation status of human macrophages presenting antigen determines the efficiency of Th17 responses
    Arnold, Christina E.
    Gordon, Peter
    Barker, Robert N.
    Wilson, Heather M.
    [J]. IMMUNOBIOLOGY, 2015, 220 (01) : 10 - 19
  • [9] Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).
    Autio, Karen A.
    Klebanoff, Christopher Austin
    Schaer, David
    Kauh, John S.
    Slovin, Susan F.
    Blinder, Victoria Susana
    Comen, Elizabeth Anne
    Danila, Daniel Costin
    Hoffman, David M. J.
    Kang, Suhyun
    McAndrew, Philomena
    Modi, Shanu
    Morris, Michael J.
    Rathkopf, Dana E.
    Sanford, Rachel Ann
    Tate, Sonya C.
    Yu, Danni
    McArthur, Heather L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] Tumor microenvironment complexity and therapeutic implications at a glance
    Baghba, Roghayyeh
    Roshangar, Leila
    Jahanban-Esfahlan, Rana
    Seidi, Khaled
    Ebrahimi-Kalan, Abbas
    Jaymand, Mehdi
    Kolahian, Saeed
    Javaheri, Tahereh
    Zare, Peyman
    [J]. CELL COMMUNICATION AND SIGNALING, 2020, 18 (01)